Bendayan R, Georgis W, Rafi-Tari S
Faculty of Pharmacy, University of Toronto, Ontario.
Pharmacotherapy. 1995 May-Jun;15(3):338-44.
In humans and various animal species, 3'-azido-3'-deoxythymidine (AZT) is in part eliminated by the kidneys, where it undergoes significant tubular secretion. The goal of this project was to develop, in a continuous renal epithelial cell line (LLCPK1), a model of AZT transport in which mechanisms of drug interactions could be investigated. Transport properties of H3-AZT were studied in LLCPK1 cells grown as monolayers on permeable filters. This system provides access to the basolateral and apical surfaces of the epithelium and allows the determination of substrate transepithelial flux from the basolateral side to the apical side (B-->A/secretory direction) and apical to basolateral side (A-->B/reabsorptive direction). The B-->A flux of AZT was significantly greater than B-->A flux of mannitol (a nontransported substrate) and was temperature dependent (37 degrees C >> 4 degrees C). The AZT A-->B flux was significantly smaller than the B-->A flux, indicating that the drug is predominantly secreted in this renal epithelium. The B-->A flux was significantly inhibited by the organic bases cimetidine, quinine, quinidine, and trimethoprim. Log concentration dose studies indicate that quinine is a weak inhibitor (IC50 = 9.61 mM) of AZT B-->A flux, and that AZT is a moderate inhibitor (IC50 = 0.69 mM) of the organic base cimetidine. These results suggest that AZT may share the organic base transporter in the renal epithelium, and that this model can be used successfully to study transport properties and renal drug-drug interactions of AZT.
在人类和各种动物物种中,3'-叠氮基-3'-脱氧胸苷(AZT)部分通过肾脏清除,在肾脏中它会经历显著的肾小管分泌。本项目的目标是在连续肾上皮细胞系(LLCPK1)中建立一个AZT转运模型,以便研究药物相互作用的机制。在生长于可渗透滤膜上的单层LLCPK1细胞中研究了H3-AZT的转运特性。该系统能够接触到上皮细胞的基底外侧和顶端表面,并允许测定底物从基底外侧到顶端表面的跨上皮通量(B→A/分泌方向)以及从顶端到基底外侧表面的通量(A→B/重吸收方向)。AZT的B→A通量显著大于甘露醇(一种非转运底物)的B→A通量,并且具有温度依赖性(37℃ >> 4℃)。AZT的A→B通量显著小于B→A通量,表明该药物在这种肾上皮细胞中主要是分泌。B→A通量受到有机碱西咪替丁、奎宁、奎尼丁和甲氧苄啶的显著抑制。对数浓度剂量研究表明,奎宁是AZT B→A通量的弱抑制剂(IC50 = 9.61 mM),而AZT是有机碱西咪替丁的中度抑制剂(IC50 = 0.69 mM)。这些结果表明,AZT可能与肾上皮细胞中的有机碱转运体共用,并且该模型可成功用于研究AZT的转运特性和肾脏药物相互作用。